Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease

Pereira, Andréa Z; Vigorito, Afonso Celso; Almeida, Alessandro de Moura; Candolo, Alexandre de Almeida; Silva, Ana Carolina Leão; Brandão-Anjos, Ana Elisa de Paula; Sá, Bianca Laselva de; Souza, Catarina Lôbo Santos de; Castro, Cláudio Galvão de; Oliveira, José Salvador Rodrigues de; Barban, Juliana Bernardo; Mancilha, Elaine Maria Borges; Todaro, Juliana; Lopes, Lilian Pinheiro; Macedo, Maria Cristina Martins de Almeida; Rodrigues, Morgani; Ribeiro, Paulo César; Silva, Roberto Luiz da; Roberto, Telma Sigolo; Rodrigues, Thays de Cássia Ruiz; Colturato, Vergílio Antônio Rensi; Paton, Eduardo José de Alencar; Barros, George Maurício Navarro; Almeida, Rosana Ducatti Souza; Moreira, Maria Cláudia Rodrigues; Flowers, Mary E.D.

doi:10.31744/einstein_journal/2020ae4799

Cited by 7 publications

(7 citation statements)

References 123 publications

(173 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most commonly used bile acid in HSCT protocols is ursodeoxycholic, and its inappropriate use at a dosage lower than that prescribed had a direct relationship with retransplantation (OR = 16.12; CI = 95%: 2.05-128.12; p = 0.001) among the participants of this study with regard to protective factors against GVHD and other liver diseases. The liver is one of the target organs of GVHD, and significant changes in the serum bilirubin and alkaline phosphatase levels may indicate involvement of this condition (22)(23)(24) .…”

Section: Discussionmentioning

confidence: 99%

Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study

Azevedo,

Ferreira Júnior,

Nascimento

et al. 2022

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

Objective: to analyze the factors associated with the failure of Hematopoietic Stem Cell Transplantation (HSCT) in patients undergoing Hematopoietic Stem Cell Retransplantation (HSCR). Method: this study implemented a quantitative approach and was a case-control type which addressed patients undergoing HSCR. To do so, a paired sample of two controls was used for each case (2:1). The case group consisted of the medical records of all patients who underwent HSCR (28) and the control group (56) of those who underwent only one transplant. Three variables guided the pairing: gender, diagnosis and type of transplant. Results: a total of 24 (85.71%) patients in the case group were re-transplanted due to disease relapse and four (14.29%) due to graft failure. There was a statistical difference in the analysis between patients who did not use ursodeoxycholic acid, opioid analgesics and immunosuppressants. The need for HSCR among those who used these medications inappropriately was 16.12, 12.79 and 4.5 times more likely, respectively, than those who used them correctly. Conclusion: there was a difference regarding the reasons which led to the retransplantation and the analyzed subjects, and this study concluded that the predictive reason for retransplantation in the studied sample was disease relapse.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study

Azevedo,

Ferreira Júnior,

Nascimento

et al. 2022

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Análise dos fatores associados ao retransplante de células-tronco hematopoiéticas: estudo caso-controle

Azevedo

Júnior

Nascimento

et al. 2022

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

Resumo Objetivo: analisar os fatores associados ao insucesso do Transplante de Células-Tronco Hematopoiéticas (TCTH) em pacientes submetidos ao retransplante de Células-Tronco Hematopoiéticas (RCTH). Método: estudo quantitativo do tipo caso-controle para avaliar pacientes submetidos ao RCTH. Para tanto, utilizou-se amostra pareada de dois controles para cada caso (2:1). O grupo caso foi constituído pelos prontuários de saúde com todos os pacientes que foram submetidos ao RCTH (28) e o grupo controle (56) incluiu pacientes que receberam apenas um transplante. Três variáveis nortearam o pareamento: sexo, diagnóstico e tipo de transplante. Resultados: vinte e quatro (85,71%) pacientes do grupo caso receberam retransplante devido a recidiva da doença e quatro (14.29%) devido a falha do enxerto. Uma diferença estatística foi encontrada na análise entre os pacientes que não usaram o ácido ursodesoxicólico, analgésicos opioides ou imunossupressores. A necessidade de um RCTH entre aqueles que usaram estes medicamentos de forma inapropriada foi 16,12, 12,79 e 4,5 vezes maior, respectivamente, do que entre os que as usaram corretamente. Conclusão: houve uma diferença relacionada ao motivo que levou ao retransplante e os indivíduos analisados. A conclusão é que a razão preditiva para retransplante nesta amostra foi a recidiva da doença.

show abstract

“…The risk of mortality might be twice as high in the HSCT when malnourished [ 15 , 27 , 29 ]. To prevent it, assembling adequate planning and support for the nutrition of patients who undergo HSCT, nutritional risk assessment, and screening are required [ 17 , 30 , 31 ]. The American Society for Parenteral and Enteral Nutrition (ASPEN) declares that nutritional treatment of all patients with haematooncological disorders should be initiated from the correct nutritional assessment [ 23 ].…”

Section: Nutritional Assessment and Screeningmentioning

confidence: 99%

“…Body structure should be consistently assessed in patients undergoing HSCT. The body weight, skin fold thickness, and arm and arm muscle diameter are measured, and BMI should be calculated [ 31 , 40 , 41 ]. However, there are many conditions and parameters which might present as a limitation for this type of nutritional assessment in haemato-oncological patients undergoing HSCT.…”

Section: Nutritional Assessment and Screeningmentioning

confidence: 99%

The Critical Exploration into Current Evidence behind the Role of the Nutritional Support in Adult Patients Who Undergo Haematogenic Stem Cell Transplantation

et al. 2023

View full text Add to dashboard Cite

Haematopoietic stem cell transplantation (HSCT) is a treatment option for many haematological conditions in patients of all ages. Nutritional support is important at each stage of treatment, but particular nutritional needs and dictated support occur during the preparatory (conditioning regimen) and post-transplant periods. Patients may require nutritional treatment by the enteral or parenteral route. The quantitative and qualitative composition of meals may change. Vitamin requirements, including vitamin D and vitamin C, might also be different. An adequately composed diet, adapted to the needs of the patient, may influence the occurrence of complications such as graft-versus-host disease (GvHD), gastrointestinal disorders, infections, and reduced survival time. Haematological diseases as well as transplantation can negatively affect the intestinal flora, with negative consequences in the form of mucosal inflammation and disorders of a functional nature. Currently, aspects related to nutrition are crucial in the care of patients after HSCT, and numerous studies, including randomized trials on these aspects, are being conducted. This study serves the critical analysis of current scientific evidence regarding nutritional support for patients after HSCT.

show abstract

Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease

Cited by 7 publications

References 123 publications

Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study

Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study

Análise dos fatores associados ao retransplante de células-tronco hematopoiéticas: estudo caso-controle

The Critical Exploration into Current Evidence behind the Role of the Nutritional Support in Adult Patients Who Undergo Haematogenic Stem Cell Transplantation

Contact Info

Product

Resources

About